Compare Johnson & Johnson (JNJ) vs Nasdaq100 ETF (QQQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Johnson & Johnson vs Nasdaq100 ETF — how do they compare? Johnson & Johnson trades at $250.32 (market cap $598.96B), while Nasdaq100 ETF trades at $706.44. The key difference: Johnson & Johnson pays a 2.15% dividend while Nasdaq100 ETF pays none. Which is the better fit depends on your goals.
| JNJ | QQQ | |
|---|---|---|
Market Cap | $598.96B | — |
Volume | 6,156,228 | — |
Sector | Health | — |
52-Week High | $267.24 | $746.16 |
52-Week Low | $164.36 | $553.88 |
Enterprise Value | $631.90B | — |
Dividend Yield | 2.15% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Johnson & Johnson (JNJ) trades at $249.58, down 1.37% today, amid a generally bullish technical outlook with strong moving average signals. The company reported robust Q2 2026 earnings, beating EPS estimates and raising full-year guidance, with revenue growth to $94.19B in 2025 and a net income margin of 21.48%. Recent news highlights strong institutional interest and positive analyst sentiment, though the stock faces pressure from MedTech segment misses despite overall strength.
The outlook for JNJ remains positive, supported by solid fundamentals, a consistent dividend history, and upward revised earnings guidance. Key risks include competitive pressures in pharmaceuticals, regulatory hurdles, and execution challenges in the MedTech division. With a consensus price target of $279.33, representing ~12% upside, the stock offers a compelling opportunity for long-term investors, balanced by sector-specific volatility and macroeconomic factors.
QQQ trades at $696.06, up 0.1% on the day, with technical indicators showing a bearish trend amid neutral oscillators. The ETF faces mixed analyst sentiment with a 50% buy and 50% sell consensus. Recent news highlights concentration in big tech and institutional position adjustments, while a future dividend of $0.81 is scheduled for July 2026.
Outlook remains cautious due to technical bearishness and divided analyst views. Key risks include tech sector volatility and macroeconomic factors influencing rate decisions. Upside potential hinges on sustained AI-driven growth, but investors should weigh concentration risks in Nasdaq-100 holdings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →About Nasdaq100 ETF
The ETF is designed to track the performance of the securities and the stocks in the NASDAQ-100 Index. To maintain the composition and weightings, the advisor adjusts the ETF from time to time to conform to periodic changes in the index target.
Read more on QQQ →
